ANVS Stock Forecast: Annovis Bio, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Annovis Bio, Inc. is $9. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 16 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Annovis Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (63): Analysts have, on balance, been raising their forecasts.
Momentum (12): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ANVS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ANVS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Nov 2026 | Roth Capital | Reiterates | Buy | $7.00 → $3.00 |
| 28 Aug 2026 | Roth Capital | Maintains | Buy | $8.00 → $7.00 |
| 18 Aug 2026 | Canaccord Genuity | Maintains | Buy | $17 |
| 8 July 2026 | Roth Capital | Initiates | Buy | $8.00 |
| 14 Apr 2026 | Canaccord Genuity | Maintains | Buy | — |
| 30 Sept 2025 | Canaccord Genuity | Maintains | Buy | — |
| 3 Sept 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 June 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 May 2025 | Canaccord Genuity | Maintains | Buy | — |
| 10 Feb 2025 | D. Boral Capital | Downgrade | Hold | — |
| 11 Nov 2024 | D. Boral Capital | Maintains | Buy | — |
| 11 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Oct 2024 | Maxim Group | Upgrade | Buy | — |
| 16 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | $30 |
| 15 Oct 2024 | EF Hutton | Maintains | Buy | $21 |
| 1 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | $30 |
| 15 Aug 2024 | EF Hutton | Maintains | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Aug 2024 | EF Hutton | Initiates | Buy | — |
| 17 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ANVS.
This page is one stock. Monday covers all of them.
ANVS appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ANVS vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Annovis Bio, Inc. returned −81.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ANVS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −142.4%
- Dividend yield
- —
Higher than 1% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Annovis Bio, Inc. has a market value of $46.4M and an enterprise value of $20.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$49.5M.
Free cash flow in the twelve months to 30 June 2026: −$43.3M.
Annovis Bio, Inc. employs 7 people.
Data provided by Twelve Data
ANVS and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ANVS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Annovis Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ANVS
What is the ANVS stock price forecast for 2026-2027?
The median 12-month analyst price target for Annovis Bio, Inc. is $9, with estimates ranging from $3 to $17. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ANVS stock a buy right now?
Of the 4 analysts covering Annovis Bio, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Annovis Bio, Inc. 16 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ANVS?
As at 21 Nov 2026, Annovis Bio, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (63 of 100).
Will ANVS stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts is $9, and Ticker Nerd's factor model ranks Annovis Bio, Inc. 16 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ANVS stock forecast for 2030?
No analyst covering Annovis Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANVS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $17 over the next 12 months.
How has ANVS stock performed over the past year?
Annovis Bio, Inc. returned -81.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Annovis Bio, Inc. do?
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. Its current pipeline centers on oral small-molecule candidates designed to address disorders such as Alzheimer’s disease and Parkinson’s disease, with additional programs targeting traumatic brain injury, stroke, Lewy body dementia, and advanced Alzheimer’s disease.
About Annovis Bio, Inc.
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. Its current pipeline centers on oral small-molecule candidates designed to address disorders such as Alzheimer’s disease and Parkinson’s disease, with additional programs targeting traumatic brain injury, stroke, Lewy body dementia, and advanced Alzheimer’s disease. The company’s lead candidate, buntanetap, is being studied for chronic neurodegeneration, while ANVS405 and ANVS301 extend its research into acute and later-stage neurological conditions. Annovis Bio’s work is directed at central nervous system disorders where protein misfolding, neuroinflammation, and cognitive decline play key roles. Based in Malvern, Pennsylvania, Annovis Bio operates as a research-driven drug development company within the biotechnology sector.
CEO Dr. Maria L. Maccecchini Ph.D. · 7 employees · United States · https://www.annovisbio.com